Background: Moyamoya disease (MMD) in children was rarely associated with intracranial aneurysms. The purpose of this study was to report the clinical characteristics and long-term surgical outcomes of pediatric intracranial aneurysms accompanied with MMD.
Methods: Between October 2002 and October 2013, our department treated 9 pediatric MMD patients (aged ≤17 years) with intracranial aneurysms. Clinical and angiographic features, treatment selection, as well as follow-up information were obtained and analyzed. The efficacy of vascularization and the changes of intracranial aneurysms were evaluated with digital subtraction angiography (DSA). We also collected 7 previously published reports to analyze the characteristics of this rare condition.
Results: In our series of 9 patients, 7 were male. The mean age was 11 ± 3.4 years (range 5-16). Seven patients presented with intracranial hemorrhage as the initial manifestation, while 2 patients suffered transient ischemic attacks. The most common aneurysm location was the posterior choroidal artery (4, 44.4%). One anterior choroidal artery aneurysm was completely embolized with Onyx (ev3, Irvine, California, USA). One posterior choroidal artery aneurysm failed due to inaccessibility to the parent artery. Bilateral encephalo-duro-arterio-synangiosis (EDAS) surgery was performed for all the children. During the follow-up period of 6.4 ± 2.2 years (range 3-11), spontaneous occlusion of aneurysm was observed in 4 children, including 1 child with middle cerebral artery aneurysm, 1 with lenticulostriate artery aneurysm, and 2 with posterior choroidal artery aneurysm. Good or fair vascularization was observed in all the 9 children with DSA follow-up. No patients suffered intracranial hemorrhage during the follow-up period.
Conclusions: The long-term survey showed EDAS surgery could effectively increase the cerebral blood flow and maintain good outcomes in children, which may further result in the disappearance of the intracranial aneurysms and decrease the incidence of recurrent hemorrhage.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.wneu.2016.05.039 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
A comprehensive proteomic analysis reveals novel inflammatory biomarkers in intracranial aneurysms.
J Proteomics
January 2025
Ningbo Key Laboratory of Nervous System and Brain Function, Department of Neurosurgery, The First Affiliated Hospital of Ningbo University, Ningbo, Zhejiang 315010, China; Key Laboratory of Precision Medicine for Atherosclerotic Diseases of Zhejiang Province, Ningbo, Zhejiang 315010, China. Electronic address:
Inflammation is a complex factor in the pathogenesis of intracranial aneurysms (IA), but its specific cellular inflammatory factors remain uncertain. We collected two cohorts and measured the representation of vascular inflammation-related proteins using the Olink CVD II Vascular Inflammation Panel. We subsequently validated our findings using ELISA and RT-qPCR.
View Article and Find Full Text PDFSafety of electroconvulsive therapy in the context of physiological and medical complexity: A state-of-the art review.
PCN Rep
March 2025
Division of Mental Health and Wellbeing Western Health Melbourne Victoria Australia.
Medical contraindications and complications pose challenges for electroconvulsive therapy (ECT). Most published reports are scattered across various physiological systems and individual disease conditions. This review aimed to evaluate the literature on physiological and medical complexities during ECT and discuss risk mitigation strategies in a comprehensive review.
View Article and Find Full Text PDFDevelopment and validation of machine learning-based model for hospital length of stay in patients undergoing endovascular interventional embolization for intracranial aneurysms.
World Neurosurg
January 2025
Department of Neurology, The First People's Hospital of Jingzhou, The First Affiliated Hospital of Yangtze University, Jingzhou 434000, China. Electronic address:
Objective: This study was to explore the factors associated with prolonged hospital length of stay (LOS) in patients with intracranial aneurysms (IAs) undergoing endovascular interventional embolization and construct prediction model machine learning algorithms.
Methods: Employing a retrospective cohort study design, this study collected patients with ruptured IA who received endovascular treatment at Jingzhou First People's Hospital during the inclusion period from September 2022 to December 2023. The entire dataset was randomly split into training and testing dataset with a 7:3 ratio.
Two types of arteriopathies, arteriomegaly and aneurysms, frequently develop at diverse locations in vertebrobasilar dolichoectasia patients: A retrospective analysis and a meta-analysis.
J Clin Neurosci
January 2025
Department of Neurovascular Research, Kobe City Medical Center General Hospital, 2-1-1 Minatojima Minamimachi, Chuo-ku, Kobe, Hyogo 650-0047, Japan; Department of Neurosurgery, Seijinkai Shimizu Hospital, 11-2 Yamadanakayoshimicho, Nishikyo-ku, Kyoto, Japan.
Background: Past studies have reported that vertebrobasilar dolichoectasia (VBD) patients may develop similar arteriopathies other than the vertebrobasilar system. However, the details of these VBD-related arteriopathies are still unclear.
Methods: We retrospectively enrolled patients diagnosed with VBD at two stroke centers in Japan between January 2012 and December 2023.
Clazosentan's dual edge in managing vasospasm following aneurysmal subarachnoid hemorrhage: an updated systematic review, meta-analysis, and meta-regression of clinical outcomes and safety profiles.
Neurosurg Rev
January 2025
Dow Medical College, Dow University of Health Sciences, Karachi, Pakistan.
Aneurysmal Subarachnoid Hemorrhage (aSAH), resulting from ruptured aneurysms, is a major contributor to stroke-related mortality and morbidity. Despite advances in healthcare, aSAH remains severe and often leads to complications such as cerebral vasospasm (CV), cerebral infarction, and delayed ischemic neurological deficits (DIND). Clazosentan, an endothelin receptor antagonist, has demonstrated potential in alleviating vasospasm and its associated outcomes, although evidence of its efficacy remains unclear.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!